Physician profile
John N Murimi
NPI 1245319516
$4,100.36
in general payments reported to CMS, 2019-2025
37 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $1,103 · 2021: $1,272 · 2022: $483 · 2023: $265 · 2024: $375 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $521.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $417.33 | 2019-2024 | Prolia, Evenity |
| Abbvie INC. | $403.42 | 2019-2025 | |
| Lilly USA, LLC | $309.53 | 2020-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $263.58 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $239.11 | 2020-2022 | |
| Amarin Pharma, INC. | $221.39 | 2019-2021 | |
| Pfizer INC. | $187.27 | 2019-2025 | |
| Glaxosmithkline, LLC. | $169.55 | 2020-2025 | Arexvy, Shingrix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $148.06 | 2020-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.83 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $142.81 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $121.06 | 2020-2025 | Gardasil 9, Capvaxive |
| Esperion Therapeutics, INC. | $104.81 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $66.18 | 2022-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Murimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.